Cognition Therapeutics (CGTX) Accumulated Expenses (2020 - 2026)

Cognition Therapeutics (CGTX) has reported Accumulated Expenses for 7 consecutive years, with $1.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses rose 182.33% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $1.7 million (up 182.33% YoY), while the FY2025 annual figure was $1.6 million, down 79.41% from the prior year.
• Accumulated Expenses improved to $1.7 million in Q1 2026 per CGTX's latest filing, from $1.6 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $7.6 million in Q4 2024 and bottomed at $480000.0 in Q1 2023.
• Historically, Accumulated Expenses has averaged $1.8 million across 5 years, with a median of $1.3 million in 2022.
• Annual changes were most pronounced in 2024 — Accumulated Expenses surged 554.08% — and 2025, when it sank 82.11%.
• Cognition Therapeutics' Accumulated Expenses stood at $870000.0 in 2022, then surged by 33.91% to $1.2 million in 2023, then soared by 554.08% to $7.6 million in 2024, then slumped by 79.41% to $1.6 million in 2025, then increased by 7.97% to $1.7 million in 2026.
• Business Quant data shows CGTX's Accumulated Expenses at $1.7 million in Q1 2026, $1.6 million in Q4 2025, and $1.3 million in Q3 2025.